SGLT2 Inhibitors Billing & Prior-Auth Playbook

What Is the SGLT2 Inhibitor Drug Class?

SGLT2 inhibitors block the sodium-glucose cotransporter-2 protein in the proximal renal tubule, forcing glucose excretion in urine and lowering plasma glucose independently of insulin. The class produces a modest A1c reduction of 0.5 to 1.0 percentage points but delivers outsized cardiovascular and renal protection that has reshaped guideline recommendations far beyond glycemic targets. The FDA first approved canagliflozin (Invokana) in March 2013, opening a therapeutic category that now includes four commercially available agents in the United States.

The Four Approved Agents

| Agent | Brand | Approved Doses | Year of First FDA Approval | |---|---|---|---| | Canagliflozin | Invokana | 100 mg, 300 mg | 2013 | | Dapagliflozin | Farxiga | 5 mg, 10 mg | 2014 | | Empagliflozin | Jardiance | 10 mg, 25 mg | 2014 | | Ertugliflozin | Steglatro | 5 mg, 15 mg | 2017 |

Ertugliflozin carries only the T2DM glycemic indication and lacks the cardiovascular outcomes data that support billing under HF or CKD codes. That gap matters enormously for prior-auth pathways.

Mechanism and Why It Drives Multiple ICD-10 Approvals

Beyond glucosuria, SGLT2 inhibitors reduce proximal tubular sodium reabsorption, lower intraglomerular pressure, decrease plasma volume, and modulate RAAS activity. A 2021 review in the Journal of the American College of Cardiology attributed the cardioprotective effect primarily to hemodynamic and natriuretic mechanisms rather than glycemic lowering alone. That mechanistic breadth justifies billing under I50.x (heart failure), N18.x (CKD), and E11.x (T2DM) codes depending on the clinical scenario.

FDA-Approved Indications and Corresponding ICD-10 Codes

Matching the right ICD-10 to the right agent is the single most effective step in reducing prior-auth denials. Payers adjudicate SGLT2 claims primarily by indication; the same drug billed under a non-covered code will deny even when the clinical rationale is sound.

Type 2 Diabetes (E11.x)

All four agents carry FDA approval for glycemic control in adults with T2DM as an adjunct to diet and exercise. The American Diabetes Association's 2024 Standards of Care recommend an SGLT2 inhibitor or GLP-1 receptor agonist as preferred add-on therapy for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of baseline A1c. Use E11.65 (T2DM with hyperglycemia) or E11.9 (T2DM without complications) depending on chart documentation. Attach the most recent A1c value in the PA request.

Heart Failure (I50.x)

Dapagliflozin and empagliflozin both carry FDA approval for HFrEF (LVEF <40%). In DAPA-HF (N=4,744), dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% vs. Placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) regardless of diabetes status. Full trial results are available at NEJM.org. Empagliflozin extended this benefit to HFpEF (LVEF >40%) in EMPEROR-Preserved (N=5,988), reducing the primary endpoint by 21% (HR 0.79; 95% CI 0.69 to 0.90; P<0.001). EMPEROR-Preserved results are published in NEJM.

Bill HFrEF as I50.20 or I50.22 (systolic heart failure, unspecified or chronic). Bill HFpEF as I50.30 or I50.32 (diastolic heart failure). Avoid I50.9 (unspecified) when possible; several payers require specificity to approve the HF indication.

Chronic Kidney Disease (N18.x)

Dapagliflozin (Farxiga) received FDA approval in April 2021 for CKD based on DAPA-CKD (N=4,304), which showed a 39% reduction in the composite renal or cardiovascular endpoint vs. Placebo (HR 0.61; 95% CI 0.51 to 0.72; P<0.001). DAPA-CKD was published in NEJM. Canagliflozin received a CKD label supplement following CREDENCE (N=4,401), which demonstrated a 30% reduction in the primary renal composite endpoint (HR 0.70; 95% CI 0.59 to 0.82; P=0.00001). CREDENCE results are in NEJM.

For CKD billing, code N18.3 (stage 3), N18.4 (stage 4), or N18.5 (stage 5 not on dialysis). Note that dapagliflozin's label requires eGFR >25 mL/min/1.73m2 at initiation; canagliflozin's CKD label requires eGFR >30. Document current eGFR and urine albumin-to-creatinine ratio (UACR) in every PA submission for a renal indication.

Prior-Authorization Requirements by Payer Segment

PA requirements differ dramatically across commercial plans, Medicare Part D, and Medicaid. The following section distills the most common criteria as of 2025.

Commercial Plans (Employer-Sponsored and ACA Exchange)

Most large commercial plans (Aetna, Cigna, UnitedHealthcare, CVS Caremark) place brand SGLT2 inhibitors on Tier 3 or Tier 4 with PA. Common requirements include:

• Documentation of T2DM diagnosis with A1c within the past 12 months, or
• Documentation of HF or CKD diagnosis with supporting lab values
• A trial of metformin of at least 90 days for the T2DM-only indication (metformin intolerance or contraindication as an exception)
• For HF indications: echocardiography or imaging report confirming LVEF or diastolic dysfunction within 12 months

The FDA label for empagliflozin explicitly states no eGFR minimum for the HF indication, which can be used to counter payer restrictions that impose renal thresholds for cardiac indications.

Medicare Part D

CMS does not require prior authorization at the national level for SGLT2 inhibitors, but individual Part D plan sponsors may add coverage limitations. Plans that place these drugs on non-preferred tiers must offer a coverage determination within 72 hours (24 hours for expedited requests) under 42 CFR 423.568. CMS coverage determination rules are posted on CMS.gov. The strongest Medicare PA requests cite EMPEROR-Reduced or DAPA-HF outcomes data directly in the clinical narrative; these trials enrolled patients with and without diabetes, removing any requirement for a diabetes diagnosis.

Medicaid

Medicaid fee-for-service programs in many states restrict SGLT2 inhibitors to preferred drug lists that require step therapy through metformin, sulfonylureas, and sometimes a DPP-4 inhibitor before authorizing an SGLT2 agent for T2DM. However, the CKD and HF indications often bypass step-therapy requirements because no generic alternative exists for those outcomes-driven labels. Check each state's Medicaid preferred drug list. CMS maintains a state Medicaid drug utilization review resource that links to individual state PDL documents.

Building a High-Approval PA Request

The structure of the PA submission often matters more than the volume of clinical information included.

Required Documentation Checklist

A submission missing any one of the following will likely trigger a manual review delay or outright denial:

1. ICD-10 code matching the FDA-approved indication (see Section 2 above)
2. Relevant lab values: A1c (T2DM), LVEF percentage with echocardiogram date (HF), eGFR and UACR with collection date (CKD)
3. Trial of formulary alternatives: Metformin dose and duration, reason for discontinuation if applicable
4. Outcomes trial citation: One sentence naming the trial, sample size, and endpoint reduction relevant to the patient's indication
5. Prescriber attestation: Statement that the requested agent is medically necessary for this specific patient based on the indication

The HealthRX clinical team recommends the following sentence template for the outcomes-trial field in commercial PA forms: "Per DAPA-HF (N=4,744, NEJM 2019), dapagliflozin 10 mg reduced worsening HF events and cardiovascular death by 26% regardless of diabetes status; this patient's HFrEF diagnosis (LVEF 32%, echo dated [DATE]) meets the trial enrollment criteria and the current FDA indication." Payers that receive this language approve at higher rates than those receiving generic "evidence-based" language without trial specifics.

Step-Therapy Waiver Language

When a plan requires a metformin step for the T2DM indication and the patient cannot tolerate metformin (GI toxicity, eGFR <30 for contrast procedures, B12 concerns), include the following in the PA:

• Metformin was trialed at [dose] mg/day for [duration].
• Therapy was discontinued due to [specific adverse effect documented in the chart].
• OR: Metformin is contraindicated per FDA labeling because eGFR is [value] mL/min/1.73m2.

The FDA metformin labeling updated in 2016 removes the absolute contraindication at eGFR <30 but retains cautions; use the specific eGFR value, not a generic contraindication claim, to pre-empt payer pushback.

Appeals Strategy for SGLT2 Inhibitor Denials

A first-level denial is not a final answer. Structured appeals that cite specific guideline language succeed more often than generic reconsideration requests.

First-Level Appeal: Clinical Peer-to-Peer

Request a peer-to-peer review with the plan's medical director within 30 days of denial. During the call, cite:

• The 2022 AHA/ACC/HFSA Heart Failure Guidelines, which give SGLT2 inhibitors a Class I recommendation (Level of Evidence A) for patients with symptomatic HFrEF to reduce hospitalizations and cardiovascular death.
• The 2022 KDIGO CKD guidelines, which recommend an SGLT2 inhibitor for all patients with CKD, T2DM, and eGFR >20 mL/min/1.73m2 (Grade 1A recommendation).

A Class I or Grade 1A recommendation from a major guideline body is the strongest rebuttal to a plan that denies on "insufficient evidence" grounds.

Second-Level Appeal: External Review

If the internal peer-to-peer fails, most state laws require plans to offer an independent external review within 45 days (or 72 hours for urgent cases). External reviewers are independent of the plan; they respond to guideline citations more than they respond to individual prescriber opinion. Attach the AHA/ACC/HFSA guideline pages and the relevant trial publication. The CMS external review process for Medicare Advantage is documented at CMS.gov.

Formulary Exception as a Parallel Track

While an appeal proceeds, file a formulary exception simultaneously. A formulary exception grants access at a lower tier without requiring the standard PA pathway. The legal standard for a formulary exception under Part D (42 CFR 423.578) is that no other covered drug treats the patient's condition as effectively without adverse effects. CMS formulary exception regulations are at eCFR.gov. The HF and CKD indications meet this standard because no other oral agent class has demonstrated the same magnitude of cardiovascular and renal endpoint reduction in outcomes-controlled trials.

Billing Codes, J-Codes, and Pharmacy Claim Nuances

SGLT2 inhibitors are oral agents dispensed through retail or specialty pharmacy; they do not carry J-codes. Professional billing under medical benefit (CMS-1500) applies only when a physician dispenses samples converted to a prescription during a clinical encounter, which is rare and subject to state dispensing laws.

NDC Accuracy in Pharmacy Claims

Pharmacy claims for SGLT2 inhibitors must use the exact 11-digit NDC matching the dispensed package size. Substituting a 30-count NDC when a 90-count bottle was dispensed triggers a mismatch reject. The FDA NDC directory lists all active NDCs by product. Pharmacists should verify NDC accuracy before adjudicating a claim with a new payer contract.

Combination Products

Empagliflozin/linagliptin (Glyxambi), dapagliflozin/saxagliptin (Qtern), and canagliflozin/metformin (Invokamet) file as combination products with their own NDCs. PA criteria for combination products usually mirror those of the SGLT2 component but may require separate documentation for the DPP-4 or metformin component. Check plan-specific policies before filing a combination-product PA to avoid dual-component denials.

Copay Assistance and Bridge Programs

Manufacturer copay cards (Jardiance Savings Card, Farxiga Co-Pay Card) reduce patient out-of-pocket cost to as low as $10 per month for commercially insured patients. These cards are not applicable to Medicare or Medicaid beneficiaries by federal law. For low-income Medicare patients denied SGLT2 coverage, the manufacturer patient assistance programs may provide the drug at no cost; eligibility thresholds vary by manufacturer. The NeedyMeds database tracks current eligibility criteria for each program, though this is outside the primary-source allowlist; prescribers should call manufacturer assistance lines directly.

Monitoring Parameters That Support PA Renewal

Most plans require PA renewal at 12 months. Documenting the following at renewal improves approval rates:

• A1c change from baseline (any reduction supports continuation for T2DM indication)
• HF hospitalization count in the prior 12 months vs. The 12 months before initiation
• eGFR trajectory (stabilization or slower decline rate vs. Pre-treatment slope)
• Blood pressure change (SGLT2 inhibitors lower systolic BP by 3 to 5 mmHg on average)

A 2022 meta-analysis in The Lancet (N=90,413 across 13 trials) confirmed that SGLT2 inhibitors reduce eGFR decline rate by approximately 1.5 to 2.0 mL/min/1.73m2 per year compared with placebo. Presenting this trajectory in a renewal PA provides objective evidence that the drug is achieving its intended renal effect.

Safety Documentation Required in PA Submissions

Payers occasionally require attestation of appropriate safety screening, particularly for canagliflozin given its FDA black box warning for lower-limb amputation risk. The canagliflozin FDA label black box warning requires that prescribers consider risk factors before initiating therapy.

Genital Mycotic Infections

Document that the patient was counseled on genital mycotic infection risk. This is not strictly a PA requirement but appears in some plan medical policies as a prescriber attestation field.

Diabetic Ketoacidosis Risk

Euglycemic DKA may occur with SGLT2 inhibitors, particularly perioperatively or during prolonged fasting. An FDA Drug Safety Communication from 2015 addressed this risk class-wide. Some PA forms for surgical patients include a field asking whether the drug will be held 3 to 4 days before elective surgery; answer "yes" and cite the FDA guidance.

Renal Thresholds at Initiation

Empagliflozin for HF carries no eGFR minimum per FDA labeling. Dapagliflozin for CKD requires eGFR >25. Canagliflozin for CKD requires eGFR >30. Document the specific eGFR value and collection date prominently. A submission that references "adequate renal function" without a number will often return a request for additional information, adding 5 to 10 business days to the review timeline.